Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Short term Debt (2016 - 2025)

Amphastar Pharmaceuticals has reported Short term Debt over the past 13 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put Short term Debt at $1.6 million for Q4 2025, up 601.28% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 601.28% YoY), and the annual figure for FY2025 was $1.6 million, up 601.28%.
  • Short term Debt for Q4 2025 was $1.6 million at Amphastar Pharmaceuticals, up from $923000.0 in the prior quarter.
  • Over the last five years, Short term Debt for AMPH hit a ceiling of $12.9 million in Q2 2023 and a floor of $224000.0 in Q1 2025.
  • Median Short term Debt over the past 5 years was $1.7 million (2022), compared with a mean of $2.7 million.
  • Biggest five-year swings in Short term Debt: tumbled 98.07% in 2024 and later skyrocketed 601.28% in 2025.
  • Amphastar Pharmaceuticals' Short term Debt stood at $2.2 million in 2021, then soared by 38.33% to $3.0 million in 2022, then tumbled by 85.69% to $436000.0 in 2023, then tumbled by 46.33% to $234000.0 in 2024, then skyrocketed by 601.28% to $1.6 million in 2025.
  • The last three reported values for Short term Debt were $1.6 million (Q4 2025), $923000.0 (Q3 2025), and $927000.0 (Q2 2025) per Business Quant data.